Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- El GAC AION UT gana el premio al mejor diseño exterior en los Torino Automotive Design Awards 2026Companies: Guangzhou Automobile Industry GroupTURÍN, Italia, 14 de septiembre de 2026 -- El AION UT de GAC ha ganado el premio al Mejor Diseño Exterior en el Torino Automotive Design Award (TADA) de 2026, celebrado durante el Salone Auto Torino 2026. Este galardón reconoce la distintiva identidad visual del modelo y el...
- GAC AION UT gewinnt den Preis für das beste Außendesign beim Torino Automotive Design Award 2026Companies: Guangzhou Automobile Industry GroupTURIN, Italien, 13. September 2026 -- Der AION UT von GAC wurde beim Torino Automotive Design Award (TADA) 2026, der im Rahmen des Salone Auto Torino 2026 stattfand, mit dem Preis für das beste Außendesign ausgezeichnet. Diese Auszeichnung würdigt die unverwechselbare...
- L'AION UT de GAC remporte le prix du meilleur design extérieur lors du Torino Automotive Design Award 2026Companies: Guangzhou Automobile Industry GroupTURIN, Italie, 13 septembre 2026 -- L'AION UT de GAC a remporté le prix du meilleur design extérieur lors du Torino Automotive Design Award (TADA) 2026, organisé dans le cadre du Salone Auto Torino 2026. Cette distinction récompense l'identité visuelle unique de ce modèle...
- JD.com’s 7Fresh Kitchen: “Chef Transformer” is coming！Companies: JD.comJD.com’s catering brand 7Fresh Kitchen has unveiled its first intelligent food truck, debuting at the China International Fair for Trade in Services (CIFTIS). As the “Chef Transformer”, the AI-powered vehicle delivers freshly stir-fried Chinese cuisine for visitors. The innovation gives a new pathway for Chinese cuisine to go global alongside China’s service industry upgrades.
- CAR FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Avis Budget Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Against Pentwater Capital Management LP - CARWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR), including those who bought Avis common stock to cover a short position, between February 20, 2025 and April 21, 2026, inclusive (the “Class Period”), of the important September 29, 2026 lead plaintiff deadline.
- StellantisA Civilian Legend Reimagined: Jeep® Brand Introduces 2027 Jeep Wrangler JL-2ACompanies: StellantisThe 11th drop in the Jeep® brand's Twelve 4 Twelve series, the 2027 Jeep Wrangler JL-2A celebrates the Willys CJ-2A, the first Jeep vehicle designed specifically for civilian use 2027 Jeep Wrangler JL-2A connects today's Wrangler generation to the original CJ-2A, the vehicle that launched...
- GAC AION UT Wins Best Exterior Design at the 2026 Torino Automotive Design AwardCompanies: Guangzhou Automobile Industry GroupGAC's AION UT has won Best Exterior Design at the 2026 Torino Automotive Design Award (TADA), held during Salone Auto Torino 2026. The honour recognizes the model's distinctive visual identity and GAC's commitment to creating electric vehicles...
- Kahn Swick & Foti, LLCAvis Budget Group, Inc. Notice of September 29, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Avis Budget Group, Inc. ("Avis" or the "Company") (NasdaqGS: CAR) of a class action securities lawsuit. CLASS...
- FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA TreatmentThe Muscular Dystrophy Association (MDA) marks another milestone for the neuromuscular community with the U.S. Food and Drug Administration (FDA) approval of Isembyld (apitegromab-mstn), a monthly infusion treatment for people living with spinal muscular atrophy (SMA) who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. Isembyld (apitegromab-mstn) is the first and only muscle-targeted therapy for SMA, offering new hope for children and adults living with this neuromuscular disease. SMA is a leading genetic cause of death in infants and often requires lifelong support to maintain mobility, breathing, and independence. Today, with more treatments available, people are living longer, more independent lives. Read Scholar Rock’s announcement here.
- The Greater New York Automobile Dealers AssociationNEW YORK CAR DEALERS REMEMBER 9/11 - HOW THEY CAME TOGETHER FOR NEW YORKTwenty-five years after the attacks on the World Trade Center on September 11, 2001, the Greater New York Automobile Dealers Association (GNYADA) remembers how the automobile industry pulled together to support efforts in the aftermath of the...
- Verden legger merke til det: TIME-anerkjennelse driver VinFasts globale reiseEn regnfull tirsdag morgen i Paris vil en sjåfør som venter på rødt lys på Boulevard Haussmann kanskje ikke umiddelbart plassere merket på SUV-en ved siden av seg. Tusenvis av kilometer unna kan en sjåfør i California oppleve et lignende øyeblikk når de ser det samme merket på en...
- Världen lägger märke till det: TIME-erkännande driver VinFasts globala resaEn regnig tisdagsmorgon i Paris kanske en förare som väntar vid ett rött ljus på Boulevard Haussmann inte omedelbart sätter fast märket på SUV:en bredvid sig. Tusentals mil bort kan en förare i Kalifornien ha ett liknande ögonblick när de ser samma märket på en amerikansk väg. Det är inte...